Resolution of Cystic Enhancement to Add-On Tumor Treating Electric Fields for Recurrent Glioblastoma after Incomplete Response to Bevacizumab
The NovoTTF-100A device emits alternating tumor treating electric fields (TTFields) that interfere with cytokinesis and chromosome segregation during mitosis. Because it has a similar efficacy to cytotoxic chemotherapy, the device has been approved by the United States Food and Drug Administration f...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2014-04-01
|
| Series: | Case Reports in Neurology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/362264 |